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Abstract
Background: The adenomatous polyposis coli (APC) protein is part of the destruction complex controlling
proteosomal degradation of b-catenin and limiting its nuclear translocation, which is thought to play a gate-
keeping role in colorectal cancer. The destruction complex is inhibited by Wnt-Frz and prostaglandin E2 (PGE2) - PI-
3 kinase pathways. Recent reports show that PGE2-induced phosphorylation of b-catenin by protein kinase A (PKA)
increases nuclear translocation indicating two mechanisms of action of PGE2 on b-catenin homeostasis.
Findings: Treatment of Apc
Min/+ mice that spontaneously develop intestinal adenomas with a PKA antagonist (Rp-
8-Br-cAMPS) selectively targeting only the latter pathway reduced tumor load, but not the number of adenomas.
Immunohistochemical characterization of intestines from treated and control animals revealed that expression of
b-catenin, b-catenin nuclear translocation and expression of the b-catenin target genes c-Myc and COX-2 were
significantly down-regulated upon Rp-8-Br-cAMPS treatment. Parallel experiments in a human colon cancer cell line
(HCT116) revealed that Rp-8-Br-cAMPS blocked PGE2-induced b-catenin phosphorylation and c-Myc upregulation.
Conclusion: Based on our findings we suggest that PGE2 act through PKA to promote b-catenin nuclear
translocation and tumor development in Apc
Min/+ mice in vivo, indicating that the direct regulatory effect of PKA
on b-catenin nuclear translocation is operative in intestinal cancer.
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Findings
The adenomatous polyposis coli (APC) gene is thought to
play a gate-keeping role in the tumor formation and pro-
gression and is the most commonly mutated gene in all
colorectal cancers. In humans, APC mutations can be
acquired (spontaneous CRC) or inherited as in the auto-
somal, familiar adenomatous polyposis (FAP), character-
ized by the formation of multiple colonic adenomatous
polyps [1]. Inactivation of both APC alleles (APC
-/-)i s
considered necessary for tumor formation. The APC pro-
tein forms a destruction complex with Axin, glycogen
synthase kinase 3b (GSK3b) and casein kinase 1 (CK1)
which phosphorylates b-catenin at multiple sites [2], and
targets b-catenin for ubiquitination and to degradation
by the proteasome system [3]. A defective APC protein
leads to cytoplasmic accumulation and translocation of
b-catenin to the nucleus [4]. b-catenin, originally discov-
ered as a cadherin-binding protein, has been shown to
interact with and function as a coactivator of T-cell fac-
tor/lymphocyte enhancer factor (TCF/LEF) transcription
factors. Human transcription factor 4 (hTCF-4), a TCF
family member that is expressed in human colonic
epithelium and colon carcinoma cells, transactivates tran-
scription only when associated with b-catenin [5]. The
result is expression and production of mitogenic and sur-
vival genes including c-Myc [6], cyclin D1 [7] and
cyclooxygenase-2 (COX-2) [8].
COX-2 levels are elevated in as many as 85% of human
CRCs and approximately 50% of colorectal adenomas [8].
Studies have shown that COX inhibition by non-steroidal
anti-inflammatory drugs (NSAIDS) or aspirin reduces the
risk of CRC and may be beneficial in large population
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associated with a decline in the incidence of CRC and
reduced mortality rate, although COX-2 inhibitors have
been associated with serious cardiovascular events in this
context [10]. Prostaglandin E2 (PGE2)h a sb e e ns h o w nt o
be an important mediator of COX-2 associated effects,
and PGE2 levels are elevated in CRC biopsies compared
with normal mucosa and even in patient blood samples
[11]. Beside an anti-angiogenic effect [12], COX inhibi-
tion promotes apoptosis and alters tumor growth [13].
PGE2 and COX-2 over-expression also correlates with
CRC risk and metastasis of CRC [14], making this path-
way relevant also in follow-up after treatment of the pri-
mary cancer. Furthermore, our observations show that
the PGE2 produced also inhibits anti-tumor immunity
through the EP2 prostanoid receptor - cAMP - protein
kinase A (PKA) - Csk pathway in effector T cells that
inhibit T cell activation [11].
Both the Wnt-Frz and the PGE2-EP3 pathway acting
through phosphoinositide 3-kinase (PI3K) and protein
kinase B (PKB) negatively regulates the APC destruction
complex that controls b-catenin proteosomal degrada-
tion. COX inhibitors are thought to reverse the inhibitory
effect of PGE2-EP3 receptor signaling on the APC
destruction complex promoting b-catenin degradation
and reversing the mitogenic effects. However, homozy-
gous deletion of the gene for the PGE2 receptor EP2 also
reduced the number and size of colorectal polyps in a
polyposis mouse model [15]. Furthermore, recent reports
h a v es h o w nt h a tP K Ac a np h o s p h o r y l a t eb-catenin at
Ser552 [16] and Ser675 [16,17] and that the effect of b-
catenin phosphorylation at the latter site is mediated by
non-canonical mechanism(s) that does not involve regu-
lation of the formation of the destruction complex.
While Taurin et al. show that Ser675 phosphorylation
promotes b-catenin interaction witht h et r a n s c r i p t i o n a l
coactivator CREB-binding protein in the nucleus and
does not affect b-catenin stability and intracellular loca-
tion [16], Hino et al. report that PKA phosphorylation of
t h es a m es i t es t a b i l i z e sb-catenin and affects its intracel-
lular localization [17]. These differences highlight the
complexity of regulation of Wnt-b-catenin signaling and
may relate to the experimental conditions and system
examined. Finally, PGE2 has been shown to control b-
catenin homeostasis in zebrafish stem cells by signaling
through both the EP3 receptor to the destruction com-
plex and through the EP2 and EP4 receptors via cAMP
to PKA affecting b-catenin stability [18]. Given the
importance of b-catenin as a trans-activator in CRC and
the interest in COX chemoprevention, the question of
whether the PGE2-EP2/4-cAMP-PKA pathway is also
active in controlling b-catenin levels in CRC is highly
relevant [19].
The Apc
Min/+ mouse is a well-established model of FAP
with a germline mutation in one APC allele, thus increas-
ing the probability of a double allele mutation and tumor
formation. Apc
Min/+ mice develop multiple adenomas in
the intestinal tract, mainly in the small intestine, at an
early age which can be blocked effectively by COX inhibi-
tion through NSAIDS. Here, we asked whether perturba-
tion of the EP2/4 but not the EP3 pathway by inhibition at
the level of PKA, could affect b-catenin levels and tumor
formation. We show that treatment of Apc
Min/+ mice with
a PKA antagonist, Rp-8-Br-cAMPS, reduces tumor load,
b-catenin levels and nuclear translocation as well as
expression of b-catenin target genes in Apc
Min/+ mice
in vivo.
Differential effects of COX and PKA inhibition on tumor
formation in Apc
Min/+ mice
To more closely delineate the effect of PKA in the COX-2
-P G E 2 pathway active in colorectal cancer, we treated
Apc
Min/+ mice with the PKA antagonist Rp-8-Br-cAMPS
for 6 weeks using earlier established doses (see Additional
file 1, Supplementary information) and compared the
result with that of treatment with the COX inhibitor indo-
methacin, previously shown to inhibit tumor development
in the Apc
Min/+model [20]. Phosphate buffered saline
(PBS) was used as vehicle control for the Rp-8-Br-cAMPS.
Examination revealed that indomethacin reduced the
number and area of tumors in the small intestine of the
Apc
Min/+ mice compared to PBS (from 47 to 3 tumors per
mouse and from 0.44 mm
2 to 0.10 mm
2 tumor area; P <
0.001; Figure 1A, B). The PKA antagonist Rp-8-Br-cAMPS
did not significantly reduce the number of adenomas (47
versus 43 tumors; P =0 . 3 6 8 ,F i g u r e1 A ,B ) ,b u tr e d u c e d
the tumor area by 36% (from 0.44 mm
2 to 0.28 mm
2; P <
0.001; Figure 1). Specifically, tumor load was reduced in
the distal part of the small intestine (Figure 1C). The dif-
ferential effect of COX inhibitor and PKA antagonist on
tumor numbers and tumor size indicated to us that the
mechanisms of action could be distinct and were exam-
ined in more detail in the following.
Inhibition of PKA does not affect lymphocytic tumor
infiltration or HIF-1a expression in Apc
Min/+ mice tumors
Lymphocytic tumor infiltration affects the course of
human CRC where type, density and location of immune
cells are shown to have higher prognostic power than the
classical UICC-TNM staging [21]. Furthermore, the
hypothesis of adaptive regulatory T cells (Treg) inhibiting
anti-tumor immune responses has been subject to consid-
erable interest [22]. Previously, we found that upon activa-
tion, Tregs express COX-2 and suppress effector T cells
by PGE2 - cAMP dependent mechanisms that may be of
clinical relevance in patients with CRC [11]. However,
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Page 2 of 7immunohistochemical characterization of small intestinal
tumors from PKA antagonist Rp-8-Br-cAMPS treated ani-
mals did not reveal any significant changes in the number
of CD3
+ T cells, CD8
+ cytotoxic T cells, Foxp3
+ Tregs or
CD56
+ natural killer (NK) cells (Figure 2A, B and Addi-
tional file 2, Figure S1). In contrast, levels of granzyme B
(GZMB), a protein expressed in the cytotoxic T lympho-
cytes (CD8
+ T cells) and NK cells, were reduced in Rp-8-
Br-cAMPS treated animals which may indicate more
degranulated cytotoxic cells post activation (Figure 2B).
Our observations indicate that intestinal immune
responses play a minor role in the development of the
Apc
Min/+ mice tumor load, consistent with other observa-
tions [23].
PGE2 also affects angiogenesis and up-regulates vascular
endothelial growth factor receptor-1 (VEGFR-1) in a
human colon cancer cell line [12] whereas indomethacin
inhibits the expression of VEGF and thereby angiogenesis
[24]. To assess treatments effects on angiogenesis, we
examined levels of the hypoxia-inducible transcription fac-
tor (HIF)-1a which regulates the expression of target
genes important in angiogenesis by accumulation and
translocation to the nucleus under hypoxic conditions.
While apical regions of all tumors showed higher cytoplas-
mic intensity and nuclear staining of HIF-1a, no differ-
ences between treatment groups were observed (Figure 2C
and Additional file 2, Figure S1).
PKA antagonist treatment of Apc
Min/+ mice decreases the
levels b-catenin signaling to the nucleus and of COX-2
and c-Myc expression in Apc
Min/+ mice tumors
We next examined the effect of treatment on the activity of
the PGE2- b-catenin pathway in tumor cells. As evident
from image analysis of immunohistochemically stained sec-
tions, levels of b-catenin were significantly decreased in
tumors from the animals treated with the PKA antagonist
Rp-8-Br-cAMPS compared to tumors from the control-
treated group (138 versus 117 median inverse grayscale
intensity units; P < 0.001, Figure 3A, B) Furthermore, the
median number of b-catenin positive nuclei were reduced
from 20% in tumors in the control group to 10% in tumors
in the Rp-8-Br-cAMPS treated group (P =0 . 0 2 4 ,F i g u r e3 A ,
B and Additional file 3, Figure S2). In addition, expression
of the b-catenin/TCF/LEF transcription complex-regulated
genes c-Myc and COX-2 were reduced in tumor cells upon
treatment with the PKA antagonist Rp-8-Br-cAMPS as evi-
dent from the median number of nuclei positive for c-Myc
(reduced from 60% in control to 20%; P < 0.001, Figure 3A,
B and Additional file 3, Figure S2) and from the cytoplas-
mic expression levels of the COX-2 enzyme (reduced from
136 in control to 106 median inverse grayscale intensity
units in the treated group; P < 0.001, Figure 3A, B and
Additional file 3, Figure S2).
For further quantification of the observed effects on tumor
tissue and validation of the observed effects without dilu-
tion into normal mucosa, we next looked at the regulation
of b-catenin phosphorylation and c-Myc regulation in a
human colonic cancer cell line, HCT 116 (Figure 4A and
4B). While treatment of HCT 116 colon carcinoma cells
with PGE2 for 30 min (phosphorylated b-catenin) or 1 h
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Figure 1 PKA antagonist reduces tumor load in Apc
Min/+ mice.
A. Images of developing adenomas representative of each
treatment acquired by transillumination microscopy are shown.
White bars = 500 μm. B. Number (B; left panel) and size (B; mid
panel) of spontaneously occurring tumors and distribution of tumor
size in the treatment groups (B; right panel), tumor numbers/size
class). Box plots with median (horizontal line); 25-75% (box) and 2.5-
97.5% (bar) percentiles are shown for each treatment group (n = 7-
10 as indicated). All tumors from the same animals were pooled
when comparing tumor size distribution between the groups (n =
41-585) as indicated. Mann-Whitney Rank Sum test was used to
compare the groups (SigmaPlot 11.0 (CA, USA). C. Number (C; left
panel) and size (right panel) of spontaneously occurring tumors in
the small intestine relative to the distance from the ventricle.
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Page 3 of 7(c-Myc) increased phosphorylation of both Ser552 and
Ser675 as well as c-Myc levels, treatment with indometha-
cin or Rp-8-Br-cAMPS reduced levels compared to
untreated sample. The latter indicates some basal prosta-
glandin production and PKA activation, although COX-2
levels are not sufficiently high to allow detection by Wes-
tern blot in HCT 116 cells [25] (and our observations).
Furthermore, the effect of exogenously added PGE2 on b-
catenin Ser552 and Ser 675 phosphorylation could be
blocked by Rp-8-Br-cAMPS but not to the same extent by
indomethacin which cannot inhibit the down-stream effect
of adding PGE2 to the cultures. In contrast, PGE2-
mediated upregulation of c-Myc levels could be blocked in
the presence of indomethacin, which may indicate that the
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Figure 2 Immunohistochemical characterization of lymphocytic infiltration and hypoxia status by HIF-1a in the Apc
Min/+ mice tumors.
A. Images acquired by microscopy of intestines from animals treated with PBS showing representative sections of tumor (GZMB, FOXP3) or
normal small intestinal mucosa (CD3, CD8, CD56). Images with H-E stained overview, normal mucosa and tumor are also shown (top, left and
middle three panels). B. Identifiable tumors were photographed and number of positive cells per area (n) in Rp-8-Br-cAMPS and PBS treated
animals were counted using a grid. Tumors and normal tissue from all animals in each group were examined (see Additional file 2, Figure S1 for
more representative images). Date are presented in Box plots with median (horizontal line); 25-75% (box) and 2.5-97.5% (bar) percentiles for each
treatment group. C. The intensity of the HIF-1a staining was calculated as the mean inverse grayscale intensity of tumor area (n). A
representative image from Rp-8-Br-cAMPS treated animal is shown (C; left panel) along with density staining data (C; right panel; Box plots
presented as in B, n = 18-30 tumors examined). Mann-Whitney Rank Sum test was used to compare the groups in B and C; P < 0.05 was
considered significant.
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Page 4 of 7regulation at this later time point relies more on endogen-
ously produced PGE2.
Cytoplasmic b-catenin may be targeted to proteosomal
degradation through the destruction complex consisting
of GSK3b, Axin, CK1 and APC (Figure 4C). However,
in the presence of active Wnt signaling, b-catenin accu-
mulates in the cytosol and translocates to the nucleus to
act in a mitogenic fashion by transactivation of TCF/
LEF leading to expression of target genes in a cell prolif-
eration and survival program [5]. As is well established,
the Wnt-Frz pathway inhibits the destruction complex
at the level of GSK3b, leading to less proteosomal
degradation and more nuclear translocation and activa-
tion of b-catenin [2]. Similarly, the up-regulation of
COX-2 in colorectal cancer leads to production of PGE2
which binds to the EP3 receptor leading to PI3K and
PKB activation, phosphorylation and dissociation of
GSK3b and thereby inhibition of the destruction com-
plex [26] (Figure 4C). In zebrafish stem cells, PGE2 act-
ing through an EP2/4-cAMP-PKA pathway was recently
shown to induce direct phosphorylation of b-catenin,
thereby stimulating its translocation to the nucleus and
mitogenic effect [18]. Here, we tested whether this sec-
ond pathway was providing a mitogenic drive in
intestinal cancer. Using Apc
Min/+ mice with a disturbed
b-catenin degradation, we specifically inhibited the
PGE2-cAMP pathway at the level of PKA by treating
mice with Rp-8-Br-cAMPS for 6 weeks (see, Figure 4C
for point of action). We show that this not only reduces
tumor load but also specifically inhibits b-catenin
nuclear translocation and the activation of b-catenin tar-
get genes such as c-Myc and COX-2 which may indicate
that the direct regulatory effect of PKA on b-catenin
nuclear translocation is also operative in intestinal can-
cer cells. Furthermore, the fact that COX inhibitors may
block the effect of PGE2 both in the b-catenin degrada-
tion and b-catenin nuclear translocation pathways while
Rp-8-Br-cAMPS only affects the latter may explain why
inhibitory effect of the PKA antagonist on tumor pro-
motion is comparably weaker than that of indomethacin.
Finally, our observation that COX inhibitor abolishes
tumor numbers whereas PKA antagonist reduces tumor
load but not tumor numbers may indicate that the anti-
tumorigenic and anti-proliferative effects are distinct
and relate to different points of action in PGE2 signal
pathways. It is interesting to speculate that stem cells in
crypt foci that give origin to adenomas may be more
sensitive to regulation via the Wnt-Frz and PGE2-EP3
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Figure 3 PKA antagonist treatment of Apc
Min/+ mice decreased COX-2, b-catenin and c-Myc expression in small intestinal tumor tissue.
A. The intensity of the b-catenin and COX-2 staining was calculated as the mean inverse grayscale intensity of tumor area (Image J 1.43u
software package). Percent b-catenin and c-Myc positive nuclei were also assessed. Data are presented as Box plots with median (horizontal line);
25-75% (box) and 2.5-97.5% (bar) percentiles shown for each treatment group. Median values compared with Mann-Whitney Rank Sum test
when Shapiro-Wilk Normality test failed; otherwise mean values compared by Student’s t-test. N = no. of tumors examined (tumors from every
animal in each treatment group were investigated). B. Micrographs of representative tumors from the PBS and Rp-8-Br-cAMPS (Rp-8-Br) treated
groups stained with b-catenin, c-Myc and COX-2 antibodies.
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Page 5 of 7pathways than via the EP2/4-cAMP-PGE2 pathway
whereas this balance may shift during tumor
development.
Additional material
Additional file 1: Supplementary information. Materials and Methods.
Reference List [27-29].
Additional file 2: Figure S1. Immunohistochemical staining with
indicated antibodies of tumor and normal mucosa from small intestines
from Apc
Min/+ mice treated with PBS or Rp-8-Br-cAMPS.
Additional file 3: Figure S2. Immunohistochemical staining with
indicated antibodies of tumor and normal mucosa from small intestines
from Apc
Min/+ mice treated with PBS or Rp-8-Br-cAMPS.
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